
HPV Vaccine Session

Joseph A. Bocchini, Jr., MD Chair, ACIP HPV Vaccine Work Group

Advisory Committee on Immunization Practices
Atlanta, GA
October 25, 2012

Evolution of Recommendations for HPV Vaccination in the U.S.



Quadrivalent (HPV 6,11,16,18) vaccine; Bivalent (HPV 16,18) vaccine

^{*} Can be given starting at 9 years of age; ** For MSM and immunocompromised males, quadrivalent HPV vaccine through 26 years of age

ACIP HPV Vaccine Work Group

- No major new policy issues being considered at this time
- Review of data
 - Data from Costa Rica bivalent vaccine trial oral HPV infection
 - Bivalent HPV vaccine trial end of study data
- Letter from Texas Pediatric Society
 - HPV vaccine for sexually abused children as young as 9 years
 - WG felt no further ACIP recommendation needed
 - To be included in AAP guidance and STD Treatment Guidelines

Outline of Session

- Evaluation of efficacy of HPV vaccine for prevention of oral HPV infection
 - Dr. Aimee Kreimer, NCI
- Progress in vaccine uptake and reasons for non-vaccination:
 NIS-Teen 2007-2011
 - Dr. Christina Dorell, NCIRD
- Future plans and CDC activities
 - Dr. Lauri Markowitz, NCHHSTP

ACIP HPV Vaccine WG members

CDC Staff

Robin Curtis
John Douglas

Eileen Dunne

Julianne Gee

Susan Hariri Nicole Liddon

Lauri Markowitz

Elissa Meites

Mona Saraiya

Shannon Stokley

Elizabeth Unger

Claudia Vellozzi

Harrell Chesson

WG Chair
Joseph Bocchini

ACIP Members
Tamera Coyne-Beasley
Renee Jenkins

Liasion Representatives and Ex Officio Members
Carolyn Deal (NIH)
Sandra Fryhofer (ACP)
Bruce Gellin (NVPO)
Amy Middleman (SAM)
Nancy Miller (FDA)
Jeff Roberts (FDA)
James Turner (ACHA)
Shainoor Virani (PHA Canada)
Patricia Whitley-Williams (NIMA)

Shainoor Virani (PHA Canada)
Patricia Whitley-Williams (NMA)
Rodney Willoughby (AAP)
Jane Zucker (AIM)
Richard Zimmerman (AAFP)

Other Members
Janet Englund
Sam Katz
Michael Marcy
Debbie Saslow (ACS)